Development Costs for C2B8. (a) Except as set forth below, or unless otherwise agreed to in writing by Genentech, IDEC shall bear all costs for development and obtaining Regulatory Approval of C2B8 in the Field in the Co-Promotion Territory through the date of Regulatory Approval of C2B8 in the United States, including but not limited to certain manufacturing process improvements for the current production process and using the existing cell line. Genentech agrees, however, that it shall bear the costs of the following development activities incurred in connection with C2B8 through the date of the first Regulatory Approval in the United States:
Appears in 4 contracts
Samples: Collaboration Agreement (Biogen Idec Inc.), Collaboration Agreement (Idec Pharmaceuticals Corp / De), Collaboration Agreement (Genentech Inc)
